1. Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med 2018; 24: 257-277.
2.
Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol 2021; 220: e202009045.
3.
Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev 2017; 40: 1-14.
4.
Chen B, Wang W, Lin F, Shi S, Ou S, Yu Y. LINC00470 represses cell autophagy and cisplatin sensitivity of glioma via suppressing PTEN expression. Folia Neuropathol 2023; 61: 88-96.
5.
Chen M, Zhang J. miR-186-5p inhibits the progression of oral squamous cell carcinoma by targeting ITGA6 to impair the activity of the PI3K/AKT pathway. J Oral Pathol Med 2022; 51: 322-331.
6.
Chu J, Geng G, Ai X, Jia W, Wang J, Xu B, Kong X, Kong L. LINC01291 promotes hepatocellular carcinoma development by targeting the miR-186-5p/OXSR1 axis. J Gene Med 2022; 24: e3394.
7.
Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther 2020; 5: 145.
8.
Deng YQ, Kong GY, Li S, Li F, Wen SL. Upregulation of lnc-ZNF281 inhibits the progression of glioma via the AKT/GSK-3b/b-catenin signaling pathway. J Immunol Res 2021; 2021: 5573071.
9.
Dorostgoo Z, Fattahi AS, Moosavi SS, Ghafouri-Fard S, Oskooei VK. Down-regulation of SLC16A-AS1 and LINC00900 lncRNAs in Iranian patients with breast cancer. Breast Dis 2022; 41: 521-528.
10.
Eslahi M, Dana PM, Asemi Z, Hallajzadeh J, Mansournia MA, Yousefi B. The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment. Int J Biol Macromol 2021; 168: 124-129.
11.
Ferrè F, Colantoni A, Helmer-Citterich M. Revealing proteinlncRNA interaction. Brief Bioinform 2016; 17: 106-116.
12.
Kang CM, Bai HL, Li XH, Huang RY, Zhao JJ, Dai XY, Zheng L, Qiu YR, Hu YW, Wang Q. The binding of lncRNA RP11-732M18.3 with 14-3-3 b/a accelerates p21 degradation and promotes glioma growth. EBioMedicine 2019; 45: 58-69.
13.
Langdon SP. Animal modeling of cancer pathology and studying tumor response to therapy. Curr Drug Targets 2012; 13: 1535-1547.
14.
Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199-227.
15.
Li C, Feng SY, Chen L. SET7/9 promotes H3K4me3 at lncRNA DRAIC promoter to modulate growth and metastasis of glioma. Eur Rev Med Pharmacol Sci 2020; 24: 12241-12250.
16.
Li J, Liu D, Cui Z. Circ_001680 stimulates glioma progression with the involvement of miR-186-5p. Eur Rev Med Pharmacol Sci 2020; 24: 6211-6218.
17.
Li S, Li Y, Chen B, Zhao J, Yu S, Tang Y, Zheng Q, Li Y, Wang P, He X, Huang S. exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. Nucleic Acids Res 2018; 46: D106-D112.
18.
Liu D, Zou Z, Li G, Pan P, Liang G. Long noncoding RNA NEAT1 suppresses proliferation and promotes apoptosis of glioma cells via downregulating miR-92b. Cancer Control 2020; 27: 1073274819897977.
19.
Liu J, Wang Y, Chu Y, Xu R, Zhang D, Wang X. Identification of a TLR-induced four-lncRNA signature as a novel prognostic biomarker in esophageal carcinoma. Front Cell Dev Biol 2020; 8: 649.
20.
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol 2014; 16: 896-913.
21.
Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013; 15 Suppl 2: ii1-56.
22.
Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017; 36: 5661-5667.
23.
Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet 2015; 52: 710-718.
24.
Qin Y, Zhang D, Zhang H, Hou L, Wang Z, Yang L, Zhang M, Zhao G, Yao Q, Ling R, Zhang J. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. Cancer Cell Int 2022; 22: 296.
25.
Tao C, Luo H, Chen L, Li J, Zhu X, Huang K. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in glioma. Bioengineered 2021; 12: 4016-4031.
26.
Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344-352.
27.
Wang F, Jiang H, Wang S, Chen B. Dual functional microRNA-186-5p targets both FGF2 and RelA to suppress tumorigenesis of glioblastoma multiforme. Cell Mol Neurobiol 2017; 37: 1433-1442.
28.
Wu WJ, Xiao F, Xiong Y, Sun GF, Guo Y, Zhou X, Hu GW, Huang K, Guo H. N6-methyladenosine (m6A)-connected lncRNAs are linked to survival and immune infiltration in glioma patients. Biosci Rep 2023; 43: BSR20222100.
29.
Xie Z, Li X, Chen H, Zeng A, Shi Y, Tang Y. The lncRNA-DLEU2/miR-186-5p/PDK3 axis promotes the progress of glioma cells. Am J Transl Res 2019; 11: 4922-4934.
30.
Zhang BL, Dong FL, Guo TW, Gu XH, Huang LY, Gao DS. MiRNAs mediate GDNF-induced proliferation and migration of glioma cells. Cell Physiol Biochem 2017; 44: 1923-1938.
31.
Zhang C, Zhang X, Wang J, Di F, Xue Y, Lin X, Zhang Y, Zhang H, Zhang Z, Gu Y. Lnc00462717 regulates the permeability of the blood-brain tumor barrier through interaction with PTBP1 to inhibit the miR-186-5p/Occludin signaling pathway. FASEB J 2020; 34: 9941-9958.
32.
Zhang Z, Zhang W, Mao J, Xu Z, Fan M. miR-186-5p functions as a tumor suppressor in human osteosarcoma by targeting FOXK1. Cell Physiol Biochem 2019; 52: 553-564.
